- Home
- NATL vs AKRO Comparison
NATL vs AKRO Comparison
Compare NATL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATL
- AKRO
- Stock Information
- Founded
- NATL 2023
- AKRO 2017
- Country
- NATL United States
- AKRO United States
- Employees
- NATL N/A
- AKRO N/A
- Industry
- NATL
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- NATL
- AKRO Health Care
- Exchange
- NATL Nasdaq
- AKRO Nasdaq
- Market Cap
- NATL 2.9B
- AKRO 3.7B
- IPO Year
- NATL N/A
- AKRO 2019
- Fundamental
- Price
- NATL $38.27
- AKRO $53.81
- Analyst Decision
- NATL Buy
- AKRO Buy
- Analyst Count
- NATL 4
- AKRO 10
- Target Price
- NATL $42.75
- AKRO $73.56
- AVG Volume (30 Days)
- NATL 346.8K
- AKRO 4.0M
- Earning Date
- NATL 11-11-2025
- AKRO 11-07-2025
- Dividend Yield
- NATL N/A
- AKRO N/A
- EPS Growth
- NATL N/A
- AKRO N/A
- EPS
- NATL 1.71
- AKRO N/A
- Revenue
- NATL $4,271,000,000.00
- AKRO N/A
- Revenue This Year
- NATL $2.73
- AKRO N/A
- Revenue Next Year
- NATL $4.51
- AKRO N/A
- P/E Ratio
- NATL $22.48
- AKRO N/A
- Revenue Growth
- NATL N/A
- AKRO N/A
- 52 Week Low
- NATL $22.30
- AKRO $21.34
- 52 Week High
- NATL $42.23
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- NATL 49.79
- AKRO 68.91
- Support Level
- NATL $37.25
- AKRO $53.40
- Resistance Level
- NATL $39.07
- AKRO $54.02
- Average True Range (ATR)
- NATL 1.31
- AKRO 0.49
- MACD
- NATL -0.11
- AKRO 0.16
- Stochastic Oscillator
- NATL 45.38
- AKRO 92.03
About NATL NCR Atleos Corporation
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.